Longeveron Inc. Aktie
LGVN
After-hours$0.80000.0000 (0.00%)
Post-Market:$0.7874-0.01 (-1.58%)
Chart wird geladen...
Longeveron Inc.
Market Cap
$25,278,362
Eröffnung0.7900
Hoch0.8201
Tief0.7900
Volumen174.61k
P/EN/A
Marktkapitalisierung25.28M
52-Wochen-Hoch1.8000
52-Wochen-Tief0.4750
Durchschn. Volumen5.5M
DividendeN/A
Beta-0.38
EPS-1.1400
Über Longeveron Inc. Aktie
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Unternehmensinformationen
Börse: NasdaqCM (NCM)
Sektor: Sundhed
Branche: Bioteknologi
Adresse:
Life Science & Technology Park
33136 Miami, United States
33136 Miami, United States
Telefon: + 844 470 2550
Webseite: https://longeveron.com
Analystenempfehlungen
Diese Übersicht gibt einen schnellen Einblick, wie Analysten das Aktienpotenzial basierend auf ihren neuesten Analysen und Kurszielen bewerten.
Niedrigstes Kursziel
3.00
↑ 275.0%
Durchschnittliches Kursziel
7.15
↑ 793.8%
Median Kursziel
8.00
↑ 900.0%
Höchstes Kursziel
10.45
↑ 1206.2%